Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 11, 2013, Pages 1397-1409

  Choong, Meng Ling ^a   Pecquet, Christian ^b   Pendharkar, Vishal ^a   Diaconu, Carmen C ^b,c   Yong, Jacklyn Wei Yan ^a   Tai, Shi Jing ^a   Wang, Si Fang ^a   Defour, Jean Philippe ^b   Sangthongpitag, Kanda ^a   Villeval, Jean Luc ^d   Vainchenker, William ^d   Constantinescu, Stefan N ^b   Lee, May Ann ^a  

^a Agency for Science   (Singapore)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

^d Universite Paris Sud   (France)

Author keywords

Combination treatment; JAK2; Kinases; Myeloproliferative neoplasms; PI3K

Indexed keywords

MUS; MUS MUSCULUS;

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; ANTINEOPLASTIC AGENT; FEDRATINIB; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PYRAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; RUXOLITINIB; SULFONAMIDE; TRIAZINE DERIVATIVE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; COMBINATION TREATMENT; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE TARGETING; GENETICS; HEMATOLOGIC DISEASE; HUMAN; JAK2; KINASES; METABOLISM; MISSENSE MUTATION; MOUSE; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASMS; NUDE MOUSE; PI3K; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

COMBINATION TREATMENT; JAK2; KINASES; MYELOPROLIFERATIVE NEOPLASMS; PI3K;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENE KNOCK-IN TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MICE; MICE, NUDE; MICE, TRANSGENIC; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PYRAZOLES; PYRROLIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 84891160533     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12156     Document Type: Article

References (59)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-8.
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352: 1779-90.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7: 387-97.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-61.
5. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007; 7: 673-83.
6. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008; 19: 385-93.
7. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3: e270.
8. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108: 3472-6.
9. Pecquet C, Staerk J, Chaligne R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010; 115: 1037-48.
10. Staerk J, Lacout C, Sato T, et al. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006; 107: 1864-71.
11. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008; 83: 359-62.
12. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999; 61: 10-5.
13. Mesa RA. New drugs for the treatment of myelofibrosis. Curr Hematol Malig Rep. 2010; 5: 15-21.
14. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366: 799-807.
15. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366: 787-98.
16. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem. 2008; 283: 5258-66.
17. Damen JE, Cutler RL, Jiao H, et al. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem. 1995; 270: 23402-8.
18. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA. 1997; 94: 3016-21.
19. Miyakawa Y, Rojnuckarin P, Habib T, et al. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem. 2001; 276: 2494-502.
20. Kamishimoto J, Tago K, Kasahara T, et al. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Cell Signal. 2011; 23: 849-56.
21. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000; 19: 5662-79.
22. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374: 1-20.
23. Foster FM, Traer CJ, Abraham SM, et al. The phosphoinositide (PI) 3-kinase family. J Cell Sci. 2003; 116: 3037-40.
24. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010; 11: 329-41.
25. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012; 366: 844-6.
26. Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012; 489: 155-9.
27. Kvasnicka H, Thiele J, Bueso-Ramos C, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica. 2013; 98(Suppl): Abstract S591.
28. Vannucchi AM, Kiladjian J-J, Cervantes F, et al. Long-term outcomes from a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF): a 3-year update of COMFORT-II. Haematologica. 2013; 98: Abstract S1111.
29. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2012; 120: Abstract 800.
30. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001; 8: 1327-38.
31. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003; 12: 1239-50.
32. Pecquet C, Diaconu CC, Staerk J, et al. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood. 2012; 119: 4625-35.
33. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983; 4: 450-4.
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
35. Marty C, Lacout C, Martin A, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010; 116: 783-7.
36. Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 2009; 421: 29-42.
37. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011; 118: 2069-76.
38. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115: 3109-17.
39. Andraos R, Qian Z, Bonenfant D, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012; 2: 512-23.
40. Khan I, Huang Z, Wen Q, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013; 27: 1882-90.
41. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-6.
42. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010; 16: 4005-15.
43. Mihu CN, Kassis C, Ramos ER, et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010; 116: 5290-6.
44. Chen Y, Alvarez EA, Azzam D, et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat. 2011; 128: 69-78.
45. Kong D, Dan S, Yamazaki K, et al. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer. 2010; 46: 1111-21.
46. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11: 2875-8.
47. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008; 454: 776-9.
48. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration. Science. 2000; 287: 1040-6.
49. Sadhu C, Masinovsky B, Dick K, et al. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol. 2003; 170: 2647-54.
50. Fiskus W, Verstovsek S, Manshouri T, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013; 12: 577-88.
51. Besancenot R, Chaligne R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010; 8: e1000476.
52. Nguyen MH, Ho JM, Beattie BK, et al. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem. 2001; 276: 32704-13.
53. Carvalho CR, Carvalheira JB, Lima MH, et al. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology. 2003; 144: 638-47.
54. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol. 2006; 291: H827-34.
55. Harir N, Pecquet C, Kerenyi M, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood. 2007; 109: 1678-86.
56. Abe M, Funakoshi-Tago M, Tago K, et al. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int Immunopharmacol. 2009; 9: 870-7.
57. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363: 1117-27.
58. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29: 789-96.
59. Vertovsek S, Kantarjian HM, Estrov Z, et al. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012; 120: 1202-9.